Does TRT Cause Prostate Cancer? What the Research Actually Shows

For decades, one fear has kept more men away from testosterone replacement therapy (TRT) than almost any other: the belief that raising testosterone fuels prostate cancer. It's a logical worry on the surface, prostate cancer cells can be sensitive to androgens, so more testosterone sounds like it should mean more risk.

But that's not what the evidence shows. Here's what the research actually says, where the real caution still belongs, and how monitoring fits into a safe TRT plan.

Where the Prostate Cancer Fear Came From

The testosterone-prostate cancer link traces back to research from the 1940s on advanced, late-stage prostate cancer, where lowering testosterone (androgen deprivation) was shown to slow tumor growth. Over time, that got generalized into a much broader and shakier idea: if less testosterone shrinks existing aggressive cancer, more testosterone must cause new cancer to form. Those are two different questions, and for years, the second one didn't have rigorous evidence behind it, it had inference.

What the Current Evidence Shows

Harvard Health Publishing has reported on this question repeatedly as the data has matured, and the pattern is increasingly consistent: appropriately prescribed, medically monitored TRT does not appear to increase prostate cancer risk in men with diagnosed low testosterone (hypogonadism).

The most rigorous evidence comes from the TRAVERSE trial, a large randomized controlled study led by researchers at Brigham and Women's Hospital and Harvard Medical School, published in JAMA Network Open in December 2023. The trial found that testosterone-treated men and placebo-treated men developed high-grade prostate cancer and other prostate-related events at statistically similar rates, meaning TRT wasn't associated with a measurable increase in risk over the study period.

This builds on earlier work. A widely cited New England Journal of Medicine analysis by Harvard urologist Dr. Abraham Morgentaler reviewed decades of prior research and reported no compelling evidence linking TRT to increased prostate cancer incidence.

The Caveats That Actually Matter

This is where a lot of social media summaries (including, candidly, oversimplified ones) lose the nuance. The reassuring data comes with real boundaries:

• The TRAVERSE trial population was specifically lower-risk. Participants were middle-aged and older men with confirmed hypogonadism and a low baseline risk of prostate cancer, followed for a defined period. The findings don't tell us how TRT affects men who are already at elevated prostate cancer risk, men using higher-than-standard doses, or men using testosterone for longer durations or for reasons outside diagnosed hypogonadism.

• It doesn't apply to men with a prostate cancer history, known prostate cancer, or elevated PSA. Every major review on this topic is explicit that these men fall outside the "no increased risk" conclusion, and existing treatment guidelines generally advise against starting TRT in men with current or high-risk prostate cancer.

• "No increased risk of new cancer" is not the same question as "is it safe if cancer is already present." Harvard's own physician commentary distinguishes between a man with a very low-risk, arguably non-aggressive prostate cancer (where testosterone's added risk appears low) and a man with high-risk disease after treatment, where reactivating existing cancer is a real theoretical concern.

• Monitoring isn't optional, it's the reason the data looks reassuring. These favorable results were observed in men receiving appropriately dosed, physician-monitored therapy, not in unsupervised or excessive use.

  
  

In other words: the myth that "TRT causes prostate cancer" is being replaced by something more accurate, but also more conditional, appropriately prescribed and monitored TRT, in the right candidate, does not appear to raise risk. That's a narrower and more useful claim than a blanket "TRT is safe for the prostate."

What Responsible Testosterone Optimization Looks Like

Given where the evidence actually stands, safe, evidence-based TRT isn't a prescription handed out on request, it's a managed process:

✔️ Comprehensive hormone and health evaluation before starting anything, including a baseline prostate exam and PSA where appropriate

✔️ Reviewing symptoms and lab results together, a low number alone isn't the whole picture; symptoms have to line up with the labs

✔️ Ongoing monitoring of testosterone, PSA, hematocrit, and other markers throughout treatment, not just at baseline

✔️ Individualized dosing, avoiding excessive doses is part of why the safety data looks favorable in the first place

✔️ Regular follow-up to catch problems early and adjust the plan as needed

Why Healthy Testosterone Levels Matter Beyond the Prostate Conversation

Testosterone isn't just about libido, it plays a role in metabolic health, muscle preservation, bone density, energy levels, mood, and long-term healthy aging. The prostate cancer question matters precisely because it's been a major (and largely outdated) barrier keeping men who could benefit from appropriate treatment away from getting evaluated at all.

The Bottom Line

The old blanket fear, "testosterone therapy causes prostate cancer", isn't supported by current evidence in appropriately selected, monitored patients. But the nuanced version matters more than the headline: this conclusion applies to men without prostate cancer or high-risk status, using appropriate doses, under medical supervision.

It is not a green light for unsupervised use, and it doesn't resolve the harder question of testosterone use after a prostate cancer diagnosis, which remains an individualized, specialist-guided decision.

Men's health is moving past one-size-fits-all myths and toward personalized, evidence-based care, and that shift cuts both ways. It means dropping outdated fears that aren't backed by data, and it means resisting the urge to oversimplify the data into "TRT is risk-free," too.

Currently treating patients located in:

Colorado, Florida, Hawaii, and Washington!

Click the link to schedule a consultation today!

https://mana-loa.clientsecure.me

-The Mana Loa Health Team

Patient safety is Mana Loa Health's top priority. The information discussed on this blog is not intended to recommend the self management of health problems or wellness. It is not intended to endorse or recommend any particular type of medical treatment or advice. The information provided on this website is for informational purposes and not a substitute for professional medical advice, diagnosis, or treatment. If you have questions or concerns about your health, please talk to your healthcare provider. No information contained on this blog should be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider.

References:

• Harvard Health Publishing, "Appropriate use of testosterone therapy does not appear to raise prostate cancer risk"

• Bhasin S, et al. JAMA Network Open. Published online December 27, 2023 (TRAVERSE trial prostate safety analysis)

• Harvard Gazette, "Study of testosterone replacement therapy not linked to prostate cancer, heart disease risk"